MDS
MDS
Advertisement
Andrew MorenoMDS | September 18, 2024
Levels for certain inflammation biomarkers in patients with MDS were similar to in patients with autoinflammatory disorders.
Read More
Andrew MorenoMDS | September 18, 2024
In pediatric, adolescent, and young adult patients, hematopoietic stem cell transplant was found to bolster overall survival.
Andrew MorenoMDS | September 18, 2024
The most common serious treatment-emergent adverse event among patients receiving either therapy was pneumonia.
Andrew MorenoMDS | August 19, 2024
A study has observed these genetic influences on disease outcome in MDS with isolated deletion of chromosome 5q.
Andrew MorenoMDS | August 16, 2024
The trial outcomes did not meet statistical significance but suggest transfusion independence achievement and good tolerance.
Andrew MorenoMDS | August 16, 2024
Phase III trial findings on MDS with chromosome 5q deletion also included improved treatment response and favorable safety.
Andrew MorenoMDS | August 14, 2024
Analysis of patients' IPSS-R scoring and bone marrow blast presence found limited benefit from pretransplant interventions.
Amer Zeidan, MBBS, MHSMDS | July 26, 2024
MDS experts tell of the clinical factors they consider when selecting from the available agent options.
Amer Zeidan, MBBS, MHSMDS | July 25, 2024
An MDS expert panel discusses findings from the trial's comparison of luspatercept with ESAs in this setting.
Andrew MorenoMDS | July 24, 2024
Phase II study data demonstrate this benefit in patients with low-risk myeloid malignancies or precursor conditions.
Andrew MorenoMDS | July 24, 2024
Final data from a phase II trial suggest a promising option for elderly patients with this serious disease.
Solly Chedid, MDMDS | July 25, 2024
Dr. Chedid brings an update highlighting the most noteworthy recent findings from MDS clinical trials.
Andrew MorenoMDS | July 17, 2024
Results from a new analysis further support the initial findings of the global, phase III IMerge trial.
Andrew MorenoMDS | June 14, 2024
This noninvasive technique is a potential improvement over bone marrow aspiration in MDS clinical evaluation and monitoring.
Heme Today Staff WritersAnemia | February 26, 2024
This would be the fourth authorized indication for luspatercept in the European Union.
Hana Safah, MDMDS | February 8, 2024
The panel shares their outlook for the future of MDS research and treatment.
Hana Safah, MDMDS | February 8, 2024
Dr. Tanaka outlines a biomarker study that observed reduced inflammation in patients with MDS treated with luspatercept.
Hana Safah, MDMDS | February 8, 2024
The panel discussed a study that assessed quality of life and PROs in patients receiving luspatercept for MDS.
Hana Safah, MDMDS | February 8, 2024
The panel discusses whether starting treatment with luspatercept sooner in patients with MDS is beneficial.
Hana Safah, MDMDS | February 8, 2024
Dr. Shammo shares her reaction to a study that assessed mutational burden and impact on primary outcomes in COMMANDS.
Advertisement
Advertisement
Advertisement
Latest News

October 3, 2024